GSK “Sincerely Apologizes” And Accepts Record $485 Million Fine For China Bribes
This article was originally published in The Pink Sheet Daily
Executive Summary
The ticket has finally been handed out. Amid a record fine for bribery, GSK says that it remains fully committed to China.
You may also be interested in...
One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: